New and Emerging Non-Postsynaptic Dopamine Modulating Antipsychotic Treatments for the Management of Patients with Schizophrenia in the Department of Veterans Affairs

Target Audience
This activity is intended for psychiatrists, psychiatric nurses, and nurse practitioners and within the VA system involved in the management of patients with schizophrenia.

Program Overview
This virtual live program has been designed to meet the educational needs of healthcare providers in the Department of Veterans Affairs, including psychiatrists involved in the management of patients with schizophrenia. We aim to help HCPs within the VA system assess the clinical benefits and disadvantages associated with dopamine-modulating antipsychotic medications approved for the management of schizophrenia and also interpret data from clinical trials assessing the clinical profiles of new and emerging therapies for the management of schizophrenia that have unique targets and mechanisms of action.

Learning Objectives
Upon completion of this activity, attendees should be able to:

Assess the clinical benefits and disadvantages associated with dopamine-modulating antipsychotic medications approved for the management of schizophrenia
Interpret data from clinical trials assessing the clinical profiles of new and emerging therapies for the management of schizophrenia that have unique targets and mechanisms of action